Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial

被引：7

作者：

Guttman-Yassky, E. ^{[1
,9
]}

Bahadori, L. ^{[2
]}

Brooks, L. ^{[3
]}

Clark, K. L. ^{[3
]}

Grindebacke, H. ^{[4
]}

Ho, C. N. ^{[5
]}

Katial, R. ^{[6
,7
]}

Pham, T. -H. ^{[8
]}

Walton, C. ^{[3
]}

Datto, C. J. ^{[2
]}

机构：

[1] Icahn Sch Med Mt Sinai, New York, NY USA

[2] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA

[3] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Cambridge, England

[4] AstraZeneca, Late Stage Dev Resp & Immunol, BioPharmaceut R&D, Gothenburg, Sweden

[5] AstraZeneca, Patient Ctr Sci, BioPharmaceut Med, Gaithersburg, MD USA

[6] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA

[7] Natl Jewish Hlth, Denver, CO USA

[8] AstraZeneca, Translat Sci & Expt Med, Early Resp & Immunol, BioPharmaceut R&D, Gaithersburg, MD USA

[9] Icahn Sch Med Mt Sinai, Kimberly & Er J Waldman Dept Dermatol, 1425 Madison Ave,Box 1047, New York, NY 10029 USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2023年 / 37卷 / 10期

关键词：

EFFICACY; SAFETY;

D O I：

10.1111/jdv.19195

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

引用

页码：E1211 / E1214

页数：4

共 50 条

[1] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Tyring, Stephen K. K.
Rich, Phoebe
Tada, Yayoi
Beeck, Stefan
Messina, Izabella
Liu, Jie
Huang, Xiaohong
Shumack, Stephen
DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
[2] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Stephen K. Tyring
Phoebe Rich
Yayoi Tada
Stefan Beeck
Izabella Messina
Jie Liu
Xiaohong Huang
Stephen Shumack
Dermatology and Therapy, 2023, 13 : 595 - 608
[3] The effect of dupilumab on vaccine antibody responses in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial
Blauvelt, A.
Simpson, E.
Wu, R.
Akinlade, B.
Graham, N.
Pirozzi, G.
Evans, R.
ALLERGY, 2016, 71 : 95 - 95
[4] Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis:: a randomized, double-blind, placebo-controlled trial
Berth-Jones, J.
Arkwright, P. D.
Marasovic, D.
Savani, N.
Aldridge, C. R.
Leech, S. N.
Morgan, C.
Clark, S. M.
Ogilvie, S.
Chopra, S.
Harper, J. I.
Smith, C. H.
Rook, G. A. W.
Friedmann, P. S.
CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (09): : 1115 - 1121
[5] Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial
Veien, NK
Busch-Sorensen, M
Stausbol-Gron, B
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (01) : 147 - 149
[6] Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Wang, Shangshang
Zhang, Litao
Liang, Yunsheng
Zhang, Shifa
Wang, Jingyan
Man, Xiaoyong
Ji, Chao
Chen, Rixin
Xiang, Guang
Meng, Zudong
Yang, Chunjun
Cheng, Hao
Wang, Qi
Li, Lin-feng
Zhang, Siping
Ding, Yanfeng
Zhu, Quangang
Qin, Lanying
Li, Yumei
Lu, Qianjin
Xia, Li
Cao, Shuanglin
Yu, Chunshui
Duan, Xinsuo
Wu, Liming
Zhang, Chunlei
Jiang, Congjun
Wang, Wei
Xu, Jinhua
DERMATOLOGIC THERAPY, 2025, 2025 (01)
[7] Results from a phase IIa randomized, double-blind, placebo-controlled, exploratory, multicentre study of GBR 830 in adults with moderate-to-severe atopic dermatitis
Guttman-Yassky, E.
Pavel, A.
Estrada, Y.
Zhang, N.
Peng, X.
Xu, H.
Wen, H.
Fang, H.
Salhi, Y.
Gudi, G.
Ca, V.
Gn, S.
Grossman, F.
Wolff, G.
BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E44 - E45
[8] EFFICACY AND SAFETY OF CM310 IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN CHINA
Zhang, Jianzhong
Yang, Bin
Li, Jingyi
Ding, Yangfeng
Wu, Liming
Zhang, Litao
Wang, Jinyan
Zhu, Xiaohong
Zhang, Furen
Tao, Xiaohua
Li, Yumei
Zhang, Chunlei
Li, Linfeng
Lu, Jianyun
Diao, Qingchun
Lu, Qianjin
Man, Xiaoyong
Li, Fuqiu
Xia, Xiujuan
Cheng, Hao
Zhao, Yan
Chen, Bo
Yan, Jinchun
Zhao, Guoqing
Jia, Yingmin
ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 20 - 20
[9] Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial
Silverberg, J. I.
Toth, D.
Bieber, T.
Alexis, A. F.
Elewski, B. E.
Pink, A. E.
Hijnen, D.
Jensen, T. N.
Bang, B.
Olsen, C. K.
Kurbasic, A.
Weidinger, S.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 450 - 463
[10] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Zhao, Yan
Zhang, Jianzhong
Yang, Bin
Li, Jingyi
Ding, Yangfeng
Wu, Liming
Zhang, Litao
Wang, Jinyan
Zhu, Xiaohong
Zhang, Furen
Tao, Xiaohua
Li, Yumei
Zhang, Chunlei
Li, Linfeng
Lu, Jianyun
Diao, Qingchun
Lu, Qianjin
Man, Xiaoyong
Li, Fuqiu
Xia, Xiujuan
Cheng, Hao
Jia, Yingmin
Zhao, Guoqing
Yan, Jinchun
Chen, Bo
CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208

← 1 2 3 4 5 →